Bridging the boundaries between scientists and clinicians—mechanistic hypotheses and patient stories in risk assessment of drugs
Author:
- 19 August 2016
- journal article
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 23 (1) , 114-120
Abstract
The cultural divide between scientists and clinicians has been described as undermining the advance of medical science, by hindering the production of practice‐relevant research and of research‐informed clinical decisions. Here, I consider the field of post‐marketing risk assessment of drugs as an example of strict interdependence between basic biomedical research, clinical research, and clinical evaluation and show how it would benefit from a closer collaboration between scientists and clinicians. The risk assessment of drugs after their marketing relies on spontaneous adverse effect reports to drug agencies and on peer‐reviewed case reports. I emphasize the importance of qualitative analysis of such reports for the improvement of mechanistic understanding of harmful effects of drugs. I argue that mechanistic explanations of drug effects are at least as important as determination of their frequency, in order to establish causation. An ideal risk assessment, then, verifies not only the frequency of undesired effects but also why and how the harm happens. For this purpose, the frequency or novelty of the unintended outcome, although contextually indicative, should not determine the epistemic value of a report. Details about the context that generated an unexpected outcome, instead, can offer the chance of improving causal understanding about how the intervention works. This is illustrated through examples from medical research. Mechanistic understanding is a domain of joint collaboration among (1) clinicians, in charge of detailed, qualitative reporting of patient stories about side effects, (2) qualitative clinical researchers, in charge of analyzing clinical contexts or harmful effects and formulating explanatory hypotheses, and (3) basic biomedical researchers, in charge of verifying such hypotheses. In addition, direct information flow can on one side focus clinicians' attention on knowledge gaps about drugs/effects where more research is needed, while on the other side create a more contextualized concept of mechanism among scientists.Keywords
This publication has 36 references indexed in Scilit:
- Protocol for a qualitative study of knowledge translation in a participatory research projectBMJ Open, 2013
- Until RCT proven? On the asymmetry of evidence requirements for risk assessmentJournal of Evaluation in Clinical Practice, 2013
- An agenda for UK clinical pharmacology: PharmacovigilanceBritish Journal of Clinical Pharmacology, 2012
- The cultural divide: exploring communication barriers between scientists and cliniciansDisease Models & Mechanisms, 2011
- The Philosophy of Evidence‐Based Medicine2011
- What Evidence in Evidence-Based Medicine?Philosophy of Science, 2002
- In Defense of Case Reports and Case SeriesAnnals of Internal Medicine, 2001
- Spontaneous Adverse Event Signaling Methods: Classification and Use with Health Care Treatment ProductsEpidemiologic Reviews, 2001
- Spontaneous reporting—of what? Clinical concerns about drugsBritish Journal of Clinical Pharmacology, 1999
- Who cares about pharmacovigilance?European Journal of Clinical Pharmacology, 1997